Biomarkers Poster lunch Poster Display session

35P_PR - Analysis of EGFR mutation status in blood and CSF in lung adenocarcinoma patients with EGFR mutation and CNS metastasis by ddPCR (ID 1934)

Presentation Number
35P_PR
Presentation Topic
Biomarkers
Lecture Time
13:00 - 13:00
Speakers
  • Y. Sen
Authors
  • Y. Sen
  • Q. Wang
Session Title
Session Room
Exhibition area, Singapore, Singapore, Singapore
Date
18.11.2017
Session Time
13:00 - 14:00

Abstract

Background

Patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations benefit a great deal from EGFR tyrosine kinase inhibitors(TKIs). However, most patients recrudesce within one or two years, and many of them progress in the central nerve system (CNS). Owing to the blood–brain barrier, detecting tumor-derived cell-free DNA (cfDNA) in the blood of brain metastasis tumor patients is challenging. Detecting tumor-specific mutations in cerebral spinal fluid (CSF) may become an alternative method.

Methods

41 initial or progressed lung adenocarcinoma patients with EGFR mutation and CNS metastasis from Henan Cancer Hospital were included in this study. 41 patients were all detected EGFR mutation status in CSF with dropplet digital PCR (ddPCR) and 37 in 41 patients were detected EGFR mutation status in blood with the same method. Their clinical information were also collected at the same time.

Results

The rate of EGFR mutations in blood (15/41, 36.6%) was obviously higher than that in CSF (24/37, 64.9%) (P = 0.013), especially in those with EGFR exon 19del mutation patients (13/16 vs 7/18, P = 0.017), without EGFR TKIs treated patients (8/11 vs 3/13, P = 0.038) and less than 60 years patients (17/22 vs 10/25, P = 0.010). In patients with CNS symptoms positive, the rate of EGFR mutations in CSF was higher than those negative (13/27 vs 2/14, P = 0.033). In patients with MRI indicating leptomeningeal metastasis, the rate of EGFR mutations in CSF was higher than those not indicating (8/11 vs 7/30, P = 0.003).

Conclusions

The EGFR mutation status in blood are different from that in CSF in patients with EGFR mutations and CNS metastasis. CNS symptoms and MRI indicating leptomeningeal metastasis are closely related with EGFR mutations status in CSF. Detecting EGFR mutation status in both extracranial and intracranial tumors will be helpful to make precise treatment, and detecting in blood and CSF with ddPCR may be an alternative.

Legal entity responsible for the study

The Affiliated Cancer Hospital of Zhengzhou University

Funding

None

Disclosure

All authors have declared no conflicts of interest.

Characteristicn (%)
Gender
Male23 (56.1)
Female18 (43.9)
Age
≥ 6016 (39)
< 6025 (61)
Smoking status
Yes12 (29.3)
No29 (70.7)
Brain metastases (MRI)
Only metastatic tumors30 (73.2)
With meningeal lesions11 (26.8)
Brain metastatic tumor number
Single10 (24.4)
Multiple31 (75.6)
Neurological symptoms
Positive15 (36.6)
Negative26 (63.4)
Prior TKIs treat
Yes28 (68.3)
No13 (31.7)
CSF EGFR mutation
197 (17.1)
216 (14.6)
Both2 (4.9)
Negative26 (63.4)
Blood EGFR mutation
1913 (31.7)
2110 (24.4)
Both1 (2.4)
Negative13 (31.7)

Collapse